Document is current
Any future updates will be listed below
-
Authors
Racioppi, Luigi https://orcid.org/0000-0002-9207-6752
Nelson, Erik R. https://orcid.org/0000-0002-8887-1905
Huang, Wei
Mukherjee, Debarati
Lawrence, Scott A.
Lento, William
Masci, Anna Maria https://orcid.org/0000-0003-1940-6740
Jiao, Yiquin
Park, Sunghee
York, Brian
Liu, Yaping
Baek, Amy E.
Drewry, David H. https://orcid.org/0000-0001-5973-5798
Zuercher, William J. https://orcid.org/0000-0002-9836-0068
Bertani, Francesca R. https://orcid.org/0000-0001-6529-8993
Businaro, Luca https://orcid.org/0000-0002-5251-093X
Geradts, Joseph
Hall, Allison
Means, Anthony R.
Chao, Nelson
Chang, Ching-yi https://orcid.org/0000-0003-2115-9574
McDonnell, Donald P. https://orcid.org/0000-0002-7331-4700
-
Funding
Funding for this research was provided by:
Susan G. Komen (IIR13264868, IIR13264868)
United States Department of Defense | United States Army | U.S. Army Corps of Engineers (CA140307, CA140307)
U.S. Department of Health & Human Services | National Institutes of Health (R00CA172357, R01CA174643)
- License Information
-
More Information
Article History
Received: 4 November 2017
Accepted: 9 May 2019
First Online: 4 June 2019
Competing interests
: The authors declare the following competing interests: L.R., E.R.N., W.H., N.C. and D.P.M. have applied for a patent covering the use of CaMKK2 inhibitors alone or in combination with immunotherapy for the treatment of cancer. Title: “CaMKK2 inhibitor compositions and methods of using the same. Racioppi, L., Nelson, E.R., Huang, W., Chao, N. and McDonnell, D.P. Provisional Patent Application No.: 62/371,309; August 5, 2016. The remaining authors declare no competing financial interests.
